ViiV Healthcare
Présence
GSK fait partie des...
- Forbes Global 2000 (#183);
- Fortune 500 Europe (#81);
- FTSE 350;
- Global Fortune 500 (#400);
- Stoxx 600;
- TOB Iconic 10,000.
GSK est une société cotée sous le symbole boursier GSK (GB).
GSK a une présence directe dans 21 pays.GSK a 24 filiales dont Aiolos Bio, GSK ANZ et GSK APAC.
Elles sont en:
- Pharmacie96%
- Biotechnologie4%
Acquisition, funding and merger involving GSK.
- GSK has announced the acquisition of Aiolos Bio (publié le 12 janvier 2024).
- GSK has announced the acquisition of Bellus Health (publié le 19 avril 2023).
Dirigeants
Voir l'organigramme avec ses 23 principaux dirigeants
Biographies les plus recherchées chez ViiV Healthcare
- Deborah Waterhouse, Chief Executive Officer and Director
- Regis Simard, Director
- David Redfern, Chairman of the Board
Changements de dirigeants chez GSK
- Jeannie Lee rejoindra l'entreprise comme Non-Executive Director le 4 mars 2024 (publié le 29 février 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez ViiV Healthcare.
Pharmacie
GSK a 1 838 concurrents dont Pfizer (Etats—Unis), Johnson & Johnson (Etats—Unis) et Sanofi (France).
Actualités en fusion/acquisition en Pharmacie.
- OXB changera son nom en OXB le Sep 18, 2024. (publié le 18 septembre 2024).
- ANI Pharmaceuticals a acquis Alimera Sciences (publié le 16 septembre 2024).
- Kintara Therapeutics and TuHura Biosciences have merged (publié le 10 septembre 2024)..
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par ViiV Healthcare
- ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil
- ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
- ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices
- ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life
- ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
- ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
- ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic
- Welsh Rugby star Gareth Thomas and ViiV Healthcare launch Tackle HIV campaign to address public misunderstanding and stigma associated with HIV
- Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
- ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de ViiV Healthcare
- ViiV Healthcare sur Wikipédia, Google News & Yahoo Finance en 1-click
- ViiV Healthcare sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont David Redfern 
Appelez ViiV Healthcare au +44 792...
